Cipla said the US FDA has issued six findings following an inspection conducted at the Goa plant in August 2022.
The drugmaker said its Goa plant recently underwent a U.S. Food and Drug Administration (US FDA) inspection from August 16 to 26, 2022. The US FDA inspected the company’s Gore manufacturing facility in September 2019. The company received it in February 2020.
Cipla further informed that as a result of the inspection, the company is currently under six observations, referring to observations made during the September 2019 inspection. There are no observations regarding data integrity.
“The company is committed to working closely with the US FDA to address these within the stipulated time.
Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generic medicines and portfolio deepening in India, South Africa, North America and its home markets of major regulated and emerging markets.
The company’s consolidated net profit decreased 4% to Rs 68.64 billion in Q1 FY2023, down 4% to Rs 537.519 billion from Q1 FY22 as gross operating income decreased by 2.3%.
On Friday’s BSE, the scrip fell 0.51% to close at 1020.25 rupees.
powered by Capital Markets – Live News
(This article is not edited by Business Standard staff and is auto-generated from a syndicated feed.)